JGC
RIGL icon

J. Goldman & Co’s Rigel Pharmaceuticals RIGL Stock Holding History

J. Goldman & Co’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,984
Closed -$32.2K – 455
2023
Q3 		$32.2K Hold
2,984
– – ﹤0.01% 340
2023
Q2 		$38.5K Hold
2,984
– – ﹤0.01% 356
2023
Q1 		$39.4K Hold
2,984
– – ﹤0.01% 336
2022
Q4 		$44.8K Hold
2,984
– – ﹤0.01% 332
2022
Q3 		$35K Sell
2,984
-13,500
-82% -$183K ﹤0.01% 353
2022
Q2 		$186K Sell
16,484
-36,507
-69% -$733K 0.01% 306
2022
Q1 		$1.58M Buy
52,991
+33,807
+176% +$915K 0.07% 212
2021
Q4 		$508K Buy
19,184
+12,150
+173% +$367K 0.03% 286
2021
Q3 		$255K Sell
7,034
-24,812
-78% -$977K 0.01% 307
2021
Q2 		$1.38M Buy
31,846
+27,023
+560% +$1.02M 0.05% 263
2021
Q1 		$165K Sell
4,823
-5,281
-52% -$209K 0.01% 407
2020
Q4 		$354K Sell
10,104
-74,145
-88% -$2.15M 0.02% 298
2020
Q3 		$2.02M Sell
84,249
-18,456
-18% -$453K 0.14% 167
2020
Q2 		$1.88M Buy
102,705
+73,405
+251% +$1.32M 0.12% 166
2020
Q1 		$457K Buy
+29,300
New +$624K 0.06% 177
2018
Q2 		– Sell
-83,250
Closed -$2.95M – 440
2018
Q1 		$2.95M Sell
83,250
-15,450
-16% -$618K 0.13% 178
2017
Q4 		$3.83M Buy
98,700
+5,200
+6% +$198K 0.2% 132
2017
Q3 		$2.38M Buy
93,500
+33,700
+56% +$820K 0.12% 178
2017
Q2 		$1.63M Buy
59,800
+10,400
+21% +$285K 0.09% 195
2017
Q1 		$1.64M Sell
49,400
-28,700
-37% -$731K 0.08% 220
2016
Q4 		$1.86M Buy
78,100
+41,997
+116% +$1.2M 0.12% 179
2016
Q3 		$1.32M Sell
36,103
-36,817
-50% -$1.06M 0.07% 219
2016
Q2 		$1.63M Buy
72,920
+31,541
+76% +$784K 0.08% 217
2016
Q1 		$861K Buy
+41,379
New +$1.02M 0.05% 234

Other funds holding RIGL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

J. Goldman & Co's RIGL Position: Q4 2023 in Review

J. Goldman & Co sold out of Rigel Pharmaceuticals (RIGL) in Q4 2023, closing a stake of 2,984 shares — an estimated $32.2K sold.

J. Goldman & Co first reported a position in RIGL in Q1 2016 and held it in 24 quarters. The position peaked at $3.83M in Q4 2017. 112 funds tracked by Wall St. Rank hold RIGL as of Q4 2023.

  • J. Goldman & Co reported no remaining Rigel Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 2,984 Rigel Pharmaceuticals shares in Q4 2023, an estimated $32.2K.
  • J. Goldman & Co first reported a position in Rigel Pharmaceuticals in Q1 2016 and held it in 24 quarters.
  • J. Goldman & Co's Rigel Pharmaceuticals position peaked at $3.83M in Q4 2017.
  • 112 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.